share_log

默沙东HIF-2α抑制剂维利瑞(贝组替凡)在华获批

TMTPost News ·  Nov 21, 2024 09:33

钛媒体App 11月21日消息,默沙东宣布,其HIF-2α抑制剂维利瑞(贝组替凡)已获得中国国家药品监督管理局(NMPA)批准,适用于治疗不需要立即手术治疗的vonHippel-Lindau(VHL)病相关肾细胞癌(RCC)、中枢神经系统(CNS)血管母细胞瘤或胰腺神经内分泌肿瘤(pNET)成人患者。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 247

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.